10.6084/m9.figshare.5124178.v1 Savelli G. Savelli G. Zaniboni A. Zaniboni A. Bertagna F. Bertagna F. Bosio G. Bosio G. Nisa L. Nisa L. Rodella C. Rodella C. Biasiotto G. Biasiotto G. Bettinsoli G. Bettinsoli G. Migliorati E. Migliorati E. Peli A. Peli A. Supplementary Material for: Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation Karger Publishers 2012 Radionuclide therapy Peptide receptors 2012-10-22 00:00:00 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Peptide_Receptor_Radionuclide_Therapy_PRRT_in_a_Patient_Affected_by_Metastatic_Breast_Cancer_with_Neuroendocrine_Differentiation/5124178 <b><i>Background: </i></b>Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies. <b><i>Case Report: </i></b>A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). Computed tomography scan and biochemical examinations showed a clear response to radionuclide therapy. <b><i>Conclusion: </i></b>PRRT may be useful in metastatic BC patients.